| Type | Title | Date Released | |
|---|---|---|---|
S-8 | Form S-8 | ||
6-K | Nasus Pharma Ltd. Announces Results of Annual and Special General Meeting of Shareholders | ||
3 | Elmaliah Oren (Reporting) | ||
4 | Rubin Eyal (Reporting) | ||
424B5 | September 2026 ATM | Offering amount: $8,500,000 | Bank: BTIG, LLC | ||
6-K | Nasus Pharma Enters Into At-The-Market Sales Agreement with BTIG | ||
6-K | Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis | ||
EFFECT | Form EFFECT | ||
6-K | Nasus Pharma Ltd. Announces Annual and Special General Meeting of Shareholders | ||
F-3 | September 2026 SHELF | ||
EFFECT | Form EFFECT | ||
6-K | Nasus Pharma Announces CFO Transition |
